ViiV Healthcare

ViiV Healthcare – Product Catalog

Single-Tablet Regimens

• Dovato → dolutegravir + lamivudine → Indication: HIV-1 infection (2-drug regimen) → Dose: Tablet 50/300 mg once daily

• Triumeq → abacavir + dolutegravir + lamivudine → Indication: HIV-1 infection → Dose: Tablet 600/50/300 mg once daily

• Triumeq PD → Pediatric formulation → Tablets for suspension (abacavir/dolutegravir/lamivudine)

• Juluca → dolutegravir + rilpivirine → Indication: HIV-1 infection (switch regimen, suppressed patients) → Dose: Tablet 50/25 mg once daily

• Tivicay PD → dolutegravir pediatric dispersible tablets → For children with HIV-1 infection → Dose: Scored dispersible tabs 5 mg

Integrase Inhibitor–Based

• Tivicay → dolutegravir → Indication: HIV-1 infection (adult & pediatric) → Dose: Tablets 50 mg once or twice daily

• Vocabria (U.S.) / Cabotegravir oral lead-in → cabotegravir → Indication: HIV-1 infection (used with rilpivirine LA) or prevention (PrEP, Apretude) → Dose: Oral tablets 30 mg daily

Long-Acting Injectables

• Cabenuva (U.S.) / Vocabria + Rekambys (EU) → cabotegravir + rilpivirine LA → Indication: Complete regimen for HIV-1 (monthly or every-2-month injection) → Dose: IM injections cabotegravir 400/600 mg + rilpivirine 600/900 mg

• Apretude → cabotegravir long-acting → Indication: HIV pre-exposure prophylaxis (PrEP) → Dose: IM injection 600 mg q2 months

NRTIs

• Ziagen → abacavir sulfate → Indication: HIV-1 infection (used in combo regimens) → Dose: Tablets 300 mg; oral solution 20 mg/mL

• Epivir → lamivudine → Indication: HIV-1 and HBV (HIV in combo, HBV monotherapy in some regions) → Dose: Tablets 150–300 mg; oral solution 10 mg/mL

NNRTIs

• Edurant (co-marketed with Janssen) → rilpivirine → Indication: HIV-1 infection (treatment-naïve with low viral load, or switch therapy) → Dose: Tablet 25 mg once daily